Chromogenic factor VIII activity assay

American Journal of Hematology

Volumn 89, Issue 7, 2014, Pages 781-784

  Moser, Karen A ^a   Adcock Funk, Dorothy M ^a  

^a LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; LUPUS ANTICOAGULANT;

ARTICLE; ASSAY; BLOOD ANALYSIS; BLOOD CLOTTING TIME; CHEMICAL LABELING; CHROMOGENIC FACTOR VIII ACTIVITY ASSAY; CLINICAL LABORATORY; COMPARATIVE EFFECTIVENESS; HEMOPHILIA A; LABORATORY TEST; METHODOLOGY; ONE STAGE CLOTTING ASSAY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SERODIAGNOSIS; TWO STAGE CLOTTING ASSAY;

CHROMOGENIC COMPOUNDS; FACTOR VIII; HUMANS;

EID: 84902797971     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23723     Document Type: Article

References (23)

1. Lundblad RL, Kingdon HS, Mann KG, White GC. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemostasis 2000;84:942-948.
2. Chandler WL, Ferrell C, Lee J, et al. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol 2003;120:34-39.
3. Kitchen S, Preston F. Assay of factor VIII and other clotting factors. In: Kitchen S, Olson J, Preston F, editors. Quality in Laboratory Hemostasis and Thrombosis, 1st ed. Chicester, West Sussex, UK: Wiley-Blackwell; 2009. pp 81-89.
4. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations. Semin Thromb Hemostasis 2002;28:247-256.
5. Kitchen S, McCraw A, Echenaguicia M. Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual., 2nd ed. Montreal, Quebec, Canada: World Federation of Hemophilia; 2010.
6. Mackie I, Cooper P, Lawrie A, et al. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 2013;35:1-13.
7. Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013;139:102-109.
8. Tichelaar V, de Jong H, Nijland H, et al. Interference of rivaroxaban in one-stage and chromogenic factor VIII: C assays. Thromb Haemostasis 2011;106:990-992.
9. Barrowcliffe T. Standardization of assays. In: Lee C, Berntorp E, Hoots W, editors. Textbook of Hemophilia. Malden, MA: Blackwell Publishing; 2005. pp 242-248.
10. Nougier C, Sobas F, Nguyen TK, et al. Analytic variability due to change of deficient plasma vials: application to one-stage clotting factor VIII assay. Blood Coagul Fibrinolysis 2011;22:151-154.
11. Butenas S, Parhami-Seren B, Undas A, et al. The "normal" factor VIII concentration in plasma. Thromb Res 2010;126:119-123.
12. Barrowcliffe TW. Laboratory testing and standardisation. Haemophilia 2013;19:799-804.
13. Eich S, Kusch M, Grundmann C, et al. Factor VIII determination in patient's plasma and concentrates: A novel test equally suited for both matrices. Blood Coagul Fibrinolysis 2003;14:347-353.
14. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994;87:846-848.
15. Cid AR, Calabuig M, Cortina V, et al. One-stage and chromogenic FVIII: C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 2008;14:1049-1054.
16. Bowyer AE, Van Veen JJ, Goodeve AC, et al. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica 2013;98:1980-1987.
17. Pipe SW, Saenko EL, Eickhorst AN, et al. Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001;97:685-691.
18. Trossaërt M, Boisseau P, Quemener A, et al. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemostasis 2011;9:524-530.
19. Rodgers SE, Duncan EM, Barbulescu DM, et al. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol 2007;136:138-145.
20. De Maistre E, Wahl D, Perret-Guillaume C, et al. A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants. Thromb Haemostasis 1998;79:237-238.
21. Blanco AN, Alcira Peirano A, Grosso SH, et al. A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant. Haematologica 2002;87:271-278.
22. Miller CH, Rice AS, Boylan B, et al. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemostasis 2013;11:1300-1309.
23. Hubbard AR, Dodt J, Lee T, et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemostasis 2013;11:988-989.